# Biotech Daily Digest — 2025-11-14

**41 items from 4 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 9 items
- Fierce Biotech: 7 items
- arXiv q-bio: 24 items


## Eli Lilly Press Releases

- **[Statement: Eli Lilly has no affiliation with Mangoceuticals, Inc.](https://investor.lilly.com/news-releases/news-release-details/statement-eli-lilly-has-no-affiliation-mangoceuticals-inc)**  
  _Thu, 13 Nov 2025 14:10:00 -0500_  
  Eli Lilly and Company (NYSE: LLY) has no affiliation with Mangoceuticals, Inc. Any communication or media report suggesting a partnership between Lilly and Mangoceuticals is false. In fact, Lilly sued Mangoceuticals last year and obtained a permanent injunction.


## Endpoints News

- **[Exclusive: The inside story of Pfizer and Novo's fight for the $10B Metsera deal](https://endpoints.news/exclusive-the-inside-story-of-pfizer-and-novos-fight-for-the-10b-metsera-deal/)**  
  _Fri, 14 Nov 2025 14:00:19 +0000_  
  Paul Berns was in the middle of a haircut when his phone rang.

 A month earlier, he had helped steer the biotech he co-founded, Metsera, to a $7.3 billion deal with Pfizer. With the deal ...

- **[Merck to buy Cidara and its preventive influenza biologic for $9.2B](https://endpoints.news/merck-to-buy-cidara-and-its-preventive-influenza-biologic-for-9-2b/)**  
  _Fri, 14 Nov 2025 12:09:54 +0000_  
  Merck said Friday it is buying Cidara Therapeutics in a deal worth $9.2 billion, centered around the biotech's late-stage preventive antiviral biologic for seasonal influenza.

 The large pharma will pay  ...

- **[Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns](https://endpoints.news/codexis-metagenomi-lead-a-cavalcade-of-new-ceos-lb-pharma-names-commercial-chief-after-ipo/)**  
  _Fri, 14 Nov 2025 12:00:22 +0000_  
  → In what appears to be another blow to Novo Nordisk, ex-Pfizer CSO Mikael Dolsten has withdrawn his nomination to join the company's board of directors due to ...

- **[UK gives drugmakers third extension to opt out of medicine rebate scheme](https://endpoints.news/uk-gives-drugmakers-third-extension-to-opt-out-of-medicine-rebate-scheme/)**  
  _Thu, 13 Nov 2025 18:39:59 +0000_  
  The UK has again extended the deadline for pharma companies to decide whether to exit the country’s drug rebate scheme.

 The UK government and the Association of the British Pharmaceutical Industry agreed to a new ...

- **[Pfizer closes up to $10B deal for obesity biotech Metsera](https://endpoints.news/pfizer-closes-up-to-10b-deal-with-obesity-biotech-metsera/)**  
  _Thu, 13 Nov 2025 17:51:38 +0000_  
  Pfizer said Thursday it has completed its up to $10 billion acquisition of obesity biotech Metsera.

 It signals the official end to a high-stakes, heated bidding war between Pfizer and Novo Nordisk that got both ...

- **[AbbVie, Alphabet’s Calico end 11-year partnership in aging research](https://endpoints.news/abbvie-alphabets-calico-end-11-year-partnership-in-aging-research/)**  
  _Thu, 13 Nov 2025 16:09:58 +0000_  
  AbbVie and Calico Life Sciences have ended their 11-year R&D partnership, a Calico spokesperson confirmed to Endpoints News.

 Calico is “fully resourced to assume full responsibility for all existing programs developed during the AbbVie collaboration ...

- **[Day One to buy struggling ADC maker Mersana for $129M](https://endpoints.news/day-one-to-buy-struggling-adc-maker-mersana-for-129m/)**  
  _Thu, 13 Nov 2025 15:54:28 +0000_  
  Day One Biopharmaceuticals is bailing out Mersana Therapeutics two years after the antibody-drug conjugate maker’s lead ovarian cancer drug failed a pivotal trial.

 Day One plans to pay $129 million upfront to buy Mersana, the ...

- **[Abeona’s skin disease cell therapy launch stymied by false-positive sterility test](https://endpoints.news/abeonas-skin-disease-cell-therapy-launch-stymied-by-false-positive-sterility-test/)**  
  _Thu, 13 Nov 2025 15:43:19 +0000_  
  Abeona Therapeutics said the commercial rollout of its rare skin disease cell therapy has hit a roadbump, delaying the treatment of its first patient by several months.

 Although the company noted on Wednesday morning that ...

- **[Q&A: BioNTech co-founders discuss immuno-oncology efforts, Bristol Myers deal](https://endpoints.news/qa-biontech-co-founders-discuss-immuno-oncology-efforts-bristol-myers-deal/)**  
  _Thu, 13 Nov 2025 15:00:44 +0000_  
  This week, BioNTech presented the industry’s most in-depth look so far at how PD-(L)1xVEGF bispecifics are being developed in cancer at its R&D Day in New York City.

 Following the event,  ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/merck-co-pays-92b-owner-influenza-antiviral-janssen-rejected" hreflang="en">Merck pays $9.2B for Cidara, picking up flu antiviral spurned by J&amp;J</a>](https://www.fiercebiotech.com/biotech/merck-co-pays-92b-owner-influenza-antiviral-janssen-rejected)**  
  _Nov 14, 2025 7:58am_  
  Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.

- **[<a href="https://www.fiercebiotech.com/biotech/bms-and-jjs-blood-thinner-flunks-phase-3-denting-big-blockbuster-hopes" hreflang="en">BMS and J&amp;J's blood thinner flunks phase 3, denting big blockbuster hopes</a>](https://www.fiercebiotech.com/biotech/bms-and-jjs-blood-thinner-flunks-phase-3-denting-big-blockbuster-hopes)**  
  _Nov 14, 2025 7:54am_  
  Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

- **[<a href="https://www.fiercebiotech.com/biotech/abbvie-cuts-ties-calico-100-scientists-after-11-year-partnership" hreflang="en">UPDATED: AbbVie to end Calico collab after 11-year run, plans layoffs: Stat</a>](https://www.fiercebiotech.com/biotech/abbvie-cuts-ties-calico-100-scientists-after-11-year-partnership)**  
  _Nov 12, 2025 12:51pm_  
  AbbVie is ending an 11-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat.

- **[<a href="https://www.fiercebiotech.com/biotech/pfizer-finalizes-metsera-buy-after-contentious-bidding-war-novo-nordisk" hreflang="en">Pfizer finalizes Metsera buy after contentious bidding war with Novo Nordisk</a>](https://www.fiercebiotech.com/biotech/pfizer-finalizes-metsera-buy-after-contentious-bidding-war-novo-nordisk)**  
  _Nov 13, 2025 12:21pm_  
  Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to swoop in and snatch the startup from under Pfizer’s nose.

- **[<a href="https://www.fiercebiotech.com/biotech/day-one-pens-285m-deal-mersana-and-its-clinical-stage-b7-h4-adc" hreflang="en">Day One pens $285M deal for Mersana and its clinical-stage B7-H4 ADC</a>](https://www.fiercebiotech.com/biotech/day-one-pens-285m-deal-mersana-and-its-clinical-stage-b7-h4-adc)**  
  _Nov 13, 2025 9:41am_  
  Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid off.

- **[<a href="https://www.fiercebiotech.com/biotech/fdas-new-plausible-mechanism-pathway-accelerate-bespoke-gene-editing-therapies" hreflang="en">UPDATED: Prasad, Makary unveil new FDA path for accelerating custom gene editing therapies</a>](https://www.fiercebiotech.com/biotech/fdas-new-plausible-mechanism-pathway-accelerate-bespoke-gene-editing-therapies)**  
  _Nov 12, 2025 3:52pm_  
  In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved.

- **[<a href="https://www.fiercebiotech.com/cro/bms-boosts-cancer-trials-sarah-cannons-clinical-research-platform" hreflang="en">BMS boosts cancer trials with Sarah Cannon's clinical research platform</a>](https://www.fiercebiotech.com/cro/bms-boosts-cancer-trials-sarah-cannons-clinical-research-platform)**  
  _Nov 12, 2025 11:45am_  
  Bristol Myers Squibb is expanding a partnership with oncology organization Sarah Cannon Research Institute, tapping into SCRI’s community-based clinical trial network.


## arXiv q-bio

- **[General Intelligence-based Fragmentation (GIF): A framework for peak-labeled spectra simulation](https://arxiv.org/abs/2511.09571)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09571v1 Announce Type: new 
Abstract: Despite growing reference libraries and advanced computational tools, progress in the field of metabolomics remains constrained by low rates of annotating measured spectra. The recent developments of large language models (LLMs) have led to strong performance across a w…

- **[Prostate-VarBench: A Benchmark with Interpretable TabNet Framework for Prostate Cancer Variant Classification](https://arxiv.org/abs/2511.09576)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09576v1 Announce Type: new 
Abstract: Variants of Uncertain Significance (VUS) limit the clinical utility of prostate cancer genomics by delaying diagnosis and therapy when evidence for pathogenicity or benignity is incomplete. Progress is further limited by inconsistent annotations across sources and the a…

- **[Exhaustive Investigation of CBC-Derived Biomarker Ratios for Clinical Outcome Prediction: The RDW-to-MCHC Ratio as a Novel Mortality Predictor in Critical Care](https://arxiv.org/abs/2511.09583)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09583v1 Announce Type: new 
Abstract: Ratios of common biomarkers and blood analytes are well established for early detection and predictive purposes. Early risk stratification in critical care is often limited by the delayed availability of complex severity scores. Complete blood count (CBC) parameters, av…

- **[Similarity Analysis of Complete Blood Count (CBC) Reference Interval Distributions Across Ethnic and Geographic Populations](https://arxiv.org/abs/2511.09584)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09584v1 Announce Type: new 
Abstract: Blood reference intervals (RIs) are central to diagnosis and therapeutic monitoring, yet most were derived from Western populations and assumed universal. This risks misclassification in regions with diverse demographic, physiological, or genetic profiles. We examined o…

- **[A master equation approach to the n-coalescent problem](https://arxiv.org/abs/2511.09594)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09594v1 Announce Type: new 
Abstract: Given an evolutionary model, such as Wright--Fisher (WF) or Moran, the n-coalescent problem consists of going backward in time to find for example the time to the most recent common ancestor (MRCA) and the topology of the tree. In the literature, this problem is tackled…

- **[Brian Intensify: An Adaptive Machine Learning Framework for Auditory EEG Stimulation and Cognitive Enhancement in FXS](https://arxiv.org/abs/2511.09765)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09765v1 Announce Type: new 
Abstract: Neurodevelopmental disorders such as Fragile X Syndrome (FXS) and Autism Spectrum Disorder (ASD) are characterized by disrupted cortical oscillatory activity, particularly in the alpha and gamma frequency bands. These abnormalities are linked to deficits in attention, s…

- **[mRNA-protein assembly reduces fluctuations in a system with bursty transcription](https://arxiv.org/abs/2511.09928)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09928v1 Announce Type: new 
Abstract: mRNA-protein assemblies play a fundamental role in forming membraneless compartments within cells, whose functions may include activating, inhibiting, and localizing reactions. Recruitment of proteins into droplets can diminish cell to cell variability in protein abunda…

- **[Imaging the Topology of Dynamic Brain Connectivity](https://arxiv.org/abs/2511.09949)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09949v1 Announce Type: new 
Abstract: Functional brain connectivity changes dynamically over time, making its representation challenging for learning on non-Euclidean data. We present a framework that encodes dynamic functional connectivity as an image representation of evolving network topology. Persistent…

- **[fastbmRAG: A Fast Graph-Based RAG Framework for Efficient Processing of Large-Scale Biomedical Literature](https://arxiv.org/abs/2511.10014)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.10014v1 Announce Type: new 
Abstract: Large language models (LLMs) are rapidly transforming various domains, including biomedicine and healthcare, and demonstrate remarkable potential from scientific research to new drug discovery. Graph-based retrieval-augmented generation (RAG) systems, as a useful applic…

- **[Representation learning in cerebellum-like structures](https://arxiv.org/abs/2511.10261)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.10261v1 Announce Type: new 
Abstract: Animals use past experiences to adapt future behavior. To enable this rapid learning, vertebrates and invertebrates have evolved analogous neural structures like the vertebrate cerebellum or insect mushroom body. A defining feature of these circuits is a large expansion…

- **[Diversity Over Scale: Whole-Slide Image Variety Enables H&E Foundation Model Training with Fewer Patches](https://arxiv.org/abs/2511.10286)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.10286v1 Announce Type: new 
Abstract: Rapid progress in computational pathology is increasingly driven by vision foundation models pretrained on vast histopathology datasets. While recent efforts have prioritized training on an ever-larger amount of patches, we take an alternative approach focused on data d…

- **[HAMscope: a snapshot Hyperspectral Autofluorescence Miniscope for real-time molecular imaging](https://arxiv.org/abs/2511.09574)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09574v1 Announce Type: cross 
Abstract: We introduce HAMscope, a compact, snapshot hyperspectral autofluorescence miniscope that enables real-time, label-free molecular imaging in a wide range of biological systems. By integrating a thin polymer diffuser into a widefield miniscope, HAMscope spectrally encod…

- **[Clinically-aligned Multi-modal Chest X-ray Classification](https://arxiv.org/abs/2511.09581)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09581v1 Announce Type: cross 
Abstract: Radiology is essential to modern healthcare, yet rising demand and staffing shortages continue to pose major challenges. Recent advances in artificial intelligence have the potential to support radiologists and help address these challenges. Given its widespread use a…

- **[Diffusion-Based Quality Control of Medical Image Segmentations across Organs](https://arxiv.org/abs/2511.09588)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09588v1 Announce Type: cross 
Abstract: Medical image segmentation using deep learning (DL) has enabled the development of automated analysis pipelines for large-scale population studies. However, state-of-the-art DL methods are prone to hallucinations, which can result in anatomically implausible segmentat…

- **[Segment Any Tumour: An Uncertainty-Aware Vision Foundation Model for Whole-Body Analysis](https://arxiv.org/abs/2511.09592)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09592v1 Announce Type: cross 
Abstract: Prompt-driven vision foundation models, such as the Segment Anything Model, have recently demonstrated remarkable adaptability in computer vision. However, their direct application to medical imaging remains challenging due to heterogeneous tissue structures, imaging…

- **[TomoGraphView: 3D Medical Image Classification with Omnidirectional Slice Representations and Graph Neural Networks](https://arxiv.org/abs/2511.09605)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09605v1 Announce Type: cross 
Abstract: The growing number of medical tomography examinations has necessitated the development of automated methods capable of extracting comprehensive imaging features to facilitate downstream tasks such as tumor characterization, while assisting physicians in managing their…

- **[Prebiotic Chemistry Insights for Dragonfly: Thermodynamics of Amino Acid Synthesis in Selk Crater on Titan](https://arxiv.org/abs/2511.09636)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09636v1 Announce Type: cross 
Abstract: Saturnian moon Titan presents a compelling testbed for probing prebiotic chemistry beyond early Earth. Impact-generated melt pools provide transient aqueous habitats in an otherwise cryogenic environment. We use Cantera equilibrium models to assess whether mixtures of…

- **[The Age-Structured Chemostat with Substrate Dynamics as a Control System](https://arxiv.org/abs/2511.09963)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09963v1 Announce Type: cross 
Abstract: In this work we study an age-structured chemostat model with a renewal boundary condition and a coupled substrate equation. The model is nonlinear and consists of a hyperbolic partial differential equation and an ordinary differential equation with nonlinear, nonlocal…

- **[Theoretical Analysis of Resource-Induced Phase Transitions in Estimation Strategies](https://arxiv.org/abs/2511.10184)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.10184v1 Announce Type: cross 
Abstract: Organisms adapt to volatile environments by integrating sensory information with internal memory, yet their information processing is constrained by resource limitations. Such limitations can fundamentally alter optimal estimation strategies in biological systems. For…

- **[Stochastic Reaction Networks Within Interacting Compartments with Content-Dependent Fragmentation](https://arxiv.org/abs/2511.10223)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2511.10223v1 Announce Type: cross 
Abstract: Stochastic reaction networks with mass-action kinetics provide a useful framework for understanding processes -- biochemical and otherwise -- in homogeneous environments. However, cellular reactions are often compartmentalized, either at the cell level or within cells…

- **[A reanalysis of the FDA's benefit-risk assessment of Moderna's mRNA-1273 COVID vaccine stratified not only based on age and sex but also on prior-infection and comorbidity status](https://arxiv.org/abs/2410.11811)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2410.11811v3 Announce Type: replace 
Abstract: The United States Food and Drug Administration (FDA) conducted a benefit-risk assessment for Moderna's COVID vaccine mRNA-1273 prior to its full approval, announced 1/31/2022. The FDA's assessment focused on males of ages 18-64 years because the agency's risk analys…

- **[How Evaluation Choices Distort the Outcome of Generative Drug Discovery](https://arxiv.org/abs/2501.05457)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2501.05457v2 Announce Type: replace 
Abstract: "How to evaluate the de novo designs proposed by a generative model?" Despite the transformative potential of generative deep learning in drug discovery, this seemingly simple question has no clear answer. The absence of standardized guidelines challenges both the b…

- **[A comparative analysis of metamodels for 0D cardiovascular models, and pipeline for sensitivity analysis, parameter estimation, and uncertainty quantification](https://arxiv.org/abs/2410.12654)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2410.12654v2 Announce Type: replace-cross 
Abstract: Zero-dimensional (0D) cardiovascular models are reduced-order models used to study global circulation dynamics and transport. They provide estimates of biomarkers (such as pressure, flow rates, and concentrations) for surgery planning and boundary conditions f…

- **[Physics of droplet regulation in biological cells](https://arxiv.org/abs/2501.13639)**  
  _Fri, 14 Nov 2025 00:00:00 -0500_  
  arXiv:2501.13639v5 Announce Type: replace-cross 
Abstract: Droplet formation has emerged as an essential concept for the spatiotemporal organisation of biomolecules in cells. However, classical descriptions of droplet dynamics based on passive liquid-liquid phase separation cannot capture the complex situation inside…
